TITLE

Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease

PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study which reveals that pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Randomized placebo-controlled trial was conducted on 5238 patients who had type 2 diabetes, hemoglobin A1c level 6.5 percent and evidence of extensive macrovascular disease. Pioglitazone use reduced a main secondary composite endpoint of all-cause mortality, nonfatal myocardial infarction and stroke, but increased the incidence of heart failure.
ACCESSION #
20297588

 

Related Articles

  • Post-infarction heart failure in Diabetes mellitus. Brkovic, Indira; Muslibegovic, Adis; Duranovic-Vinkovic, Lamija // HealthMed;2013, Vol. 7 Issue 9, p2641 

    Background: At work on internal Department we noticed frequent occurrence of heart failure postinfarctial flow in diabetics and that with severly clinical course. Materials and Methods: Retrospective study were tested total of 276 hospitalized patients in RMC "Dr.Safet Mujid "Mostar with and...

  • Assessment of the Direct Medical Costs of Type 2 Diabetes Mellitus and its Complications in Turkey. Malhan, Simten; Öksüz, Ergun; Babineaux, Steven M.; Ertekin, Ali; Palmer, James P. // Turkish Journal of Endocrinology & Metabolism;6/1/2014, Vol. 18 Issue 2, p39 

    Purpose: To estimate the direct annual medical costs of Type 2 diabetes and its complications in diagnosed patients in Turkey. Material and Method: A cost-of-illness model was developed. The prevalence of Type 2 diabetes was derived from the Turkish Diabetes Epidemiology Study, estimated as...

  • Cardiovascular risk prediction in newly diagnosed T2D. Vora, Jiten // Diabetes Digest;2013, Vol. 12 Issue 2, p102 

    The article discusses a study which aims to provide information on the degree of detail needed to assess cardiovascular risk in patients newly diagnosed with type 2 diabetes. It found out that one in six people, mostly composed of older, female and sedentary patients who do not smoke, showed...

  • Influence of admission glucose profile and hemoglobin A1c on complications of acute myocardial infarction in diabetic patients. VUJOSEVIC, S.; RADOJEVIC, N.; BELADA, N. // European Review for Medical & Pharmacological Sciences;May2013, Vol. 17 Issue 9, p1252 

    BACKGROUND: Diabetic patients have a double higher short-term mortality rate after acute myocardial infarction (AMI) than non-diabetic ones. Admission glucose level has been already concerned as an independent risk factor for the long-term prognosis after myocardial infarction. The aim of this...

  • The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. van der Leeuw, J.; van Dieren, S.; Beulens, J. W. J.; Boeing, H.; Spijkerman, A. M. W.; van der Graaf, Y.; van der A, D. L.; Nöthlings, U.; Visseren, F. L. J.; Rutten, G. E. H. M.; Moons, K. G. M.; van der Schouw, Y. T.; Peelen, L. M. // Heart;2/1/2015, Vol. 101 Issue 3, p222 

    Objective Various cardiovascular prediction models have been developed for patients w i t h type 2 diabetes. Their predictive performance in new patients is mostly not investigated. This study aims to quantify the predictive performance of all cardiovascular prediction models developed...

  • COMMENTARY: Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Isley, William L. // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p34 

    The article focuses on a study which reveals that pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Although glycemic control generally has not been shown to reduce macrovascular...

  • ROSIGLITAZONEA JOURNEY THAT NEVER COMPLETED. Gopala, Anjali; Sharma, Vinek Kumar; Ganti, Subrahmanya Sarma // International Journal of Pharmacy & Pharmaceutical Sciences;2010 Supplement 2, Vol. 2 Issue S2, p7 

    Diabetes is the major cause of mortality and morbidity leading to cardiovascular and other related complications. Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription factors of nuclear hormone receptor super family comprising of three subtypes such as PPARα,...

  • New risk score for heart failure in T2D.  // Diabetes Digest;2011, Vol. 10 Issue 3, p178 

    The article focuses on the study by R. Pfister and colleagues which shows that the risk prediction score can be used to calculate future heart failure in patients with type 2 diabetes (T2D).

  • Plasma Homocysteine level and its clinical correlation with type 2 diabetes mellitus and its complications. Sonkar, Satyendra; Sonkar, Gyanendra; Soni, Deepika; Soni, Dheeraj; Usman, Kauser // International Journal of Diabetes in Developing Countries;Mar2014, Vol. 34 Issue 1, p3 

    Homocysteine (Hcys) has been implicated to be associated with diabetes and its complications. To study the association of plasma Hcys with diabetes complications (cardiovascular disease [CVD], cerebrovascular disease [CBVD], peripheral vascular disease [PVD], nephropathy, retinopathy and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics